Eidogen-Sertanty announces issuance of U.S. patent for alignment technology

San Diego, CA (February 3, 2006) – Eidogen-Sertanty has announced that it has been issued a patent from the United States Patent and Trademark Office (USPTO) relating to its methods and systems for quickly and accurately determining the statistical significance of sequence alignments.   U.S. Patent number 6,988,039 - "Method for Determining Sequence Alignment Significance" - covers alignment algorithms and methodologies for rapid remote homology detection, which are utilized in Eidogen-Sertanty's STRUCTFAST comparative modeling technology.

About Eidogen-Sertanty, Inc.
Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations.  Eidogen-Sertanty’s unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization.  To find out more about Eidogen-Sertanty and their products and services please visit www.eidogen-sertanty.com.

Contact Information:
Steven Muskal
760-729-0211
pr@eidogen-sertanty.com